Hearing the words "stomach cancer" can feel like the ground disappears beneath you. Fear, confusion, and a flood of questions – with no time to waste. What happens next? What are the treatment options? Is there hope for recovery? This guide is here to give you clarity in the chaos. We’ve gathered clear, reliable, and up-to-date information to walk you through each step – from diagnosis to treatment planning – so you can move forward with confidence and a sense of control.
Understanding Stomach Cancer: Key Facts and Current Challenges
Stomach cancer, or gastric cancer, arises from the inner lining of the stomach and progresses through several stages if left untreated. The vast majority of cases – over 90% – are adenocarcinomas, which develop from glandular cells responsible for producing stomach acid and digestive enzymes. While the overall incidence has declined in parts of Europe, stomach cancer remains a leading cause of cancer-related deaths globally, especially due to late-stage diagnosis.
According to the European Cancer Information System (ECIS) [1], more than 130,000 new cases were diagnosed across Europe in 2022. Despite advancements in prevention and diagnostics, the 5-year survival rate remains low in advanced stages, highlighting the need for earlier detection and optimized treatment strategies.
How Stomach Cancer Develops
Gastric cancer often begins with chronic inflammation, most commonly caused by long-term infection with Helicobacter pylori (H. pylori) – a bacterium classified as a Group 1 carcinogen by NCCN guidelines [2]. Over time, this inflammation can lead to cellular changes known as intestinal metaplasia, which may progress to dysplasia and eventually invasive cancer.
Other contributing factors include genetic predispositions, a diet high in preserved or smoked foods, tobacco use, and certain inherited syndromes, such as hereditary diffuse gastric cancer (HDGC).
Classification and Staging
Accurate staging is critical to planning treatment. In Europe, the TNM classification system, harmonized with ESMO and UICC guidelines [3], is the standard method of assessing tumor spread. It incorporates findings from imaging (CT, PET-CT, endoscopic ultrasound) and, when appropriate, diagnostic laparoscopy.
- Stage I: Tumor is limited to the inner layers of the stomach wall, with no lymph node involvement. Prognosis is generally favorable if treated promptly.
- Stage II: Deeper invasion into the muscle layer or early lymph node spread. Multimodal treatment is often required.
- Stage III: Extensive local and regional spread, involving multiple lymph nodes or adjacent structures. Surgery may be possible, but it typically follows chemotherapy.
- Stage IV: Distant metastases (e.g., liver, peritoneum, lungs). At this stage, treatment is palliative, focusing on symptom control and life prolongation.
Standard Treatment Options For Stomach Cancer
The choice of gastric cancer treatment is primarily based on the tumor stage, location, histological type, molecular characteristics, and overall health status of the patient. According to the ESMO Clinical Practice Guidelines (2022) [4], a multidisciplinary approach is essential to ensure the best possible outcome, integrating input from oncology, surgery, radiology, pathology, and nutrition support.
Surgery: The Cornerstone for Curative Intent
For patients with localized or locally advanced tumors (Stage I-III), surgical resection is the most effective curative treatment. The type of stomach cancer surgery depends on the tumor’s location and extent:
- Subtotal (distal) gastrectomy: Preferred for tumors in the lower part of the stomach.
- Total gastrectomy: Required for proximal tumors or when the cancer involves large areas.
- D2 lymphadenectomy: Removal of surrounding lymph nodes is standard across Europe, in line with EAES and ESMO recommendations.
Minimally invasive stomach cancer surgery (laparoscopic or robotic) is increasingly used, particularly in early-stage disease, with similar oncologic outcomes and faster recovery times.
Perioperative and Adjuvant Chemotherapy
In patients with resectable Stage II and III stomach cancer, perioperative chemotherapy is the standard treatment approach recommended by leading European oncology guidelines, including those from the European Society for Medical Oncology (ESMO). This involves a combination of chemotherapy given both before surgery (neoadjuvant) to shrink the tumor and after surgery (adjuvant) to reduce the risk of recurrence.
The currently preferred regimen in Europe includes a four-drug combination that has shown better outcomes compared to older three-drug protocols. This strategy is based on strong evidence from large clinical trials, which demonstrated improved survival and higher rates of complete tumor removal.
Typically, gastric cancer treatment is delivered in several cycles before surgery and continued after recovery, and is best suited for patients in good overall health who can tolerate an intensive treatment course.
Targeted Therapy: When It May Be Used
In certain cases of advanced stomach cancer, tumors may exhibit specific molecular characteristics that open the door to targeted treatment approaches. One of the most clinically relevant markers is the overexpression or amplification of a particular growth factor receptor associated with tumor proliferation.
For patients whose tumors test positive for this marker, the addition of a targeted agent to standard chemotherapy has been shown to improve overall survival. This combination is now considered a first-line treatment option in such molecular subtypes, in line with the European Society for Medical Oncology (ESMO) recommendations.
Testing for this biomarker is strongly recommended before initiating systemic gastric cancer treatment in advanced disease, as it helps guide therapy decisions and ensures that patients receive the most effective and individualized treatment available.
Innovative Therapies for Gastric Cancer
In recent years, gastric cancer treatment options have expanded beyond conventional protocols. A number of advanced therapeutic approaches are now used in clinical practice across Europe to effectively address metastatic, recurrent, and peritoneal forms of the disease. These methods have demonstrated proven clinical benefit, high safety standards, and growing international adoption, offering patients new chances in cases where traditional strategies may have reached their limit.
Dendritic Cell-Based Immunotherapy: Immune Activation with Proven Scientific Foundation
Dendritic cell therapy is a clinically validated form of active immunotherapy for gastric cancer that helps the immune system recognize and attack cancer cells. Dendritic cell therapy involves isolating dendritic cells from the patient’s blood and, in a controlled laboratory setting, pulsing them with tumor-associated antigens – molecular structures derived from the patient’s cancer that serve as immunologic identifiers. These antigens are processed and presented on the surface of the dendritic cells via major histocompatibility complex (MHC) molecules.
Once prepared, the antigen-loaded dendritic cells are reintroduced into the patient, typically via intradermal injection. They migrate to regional lymph nodes, where they interact with naïve T-lymphocytes, initiating a cytotoxic T-cell response directed specifically against tumor cells expressing the same antigens.
The scientific foundation of this method was established by Dr. Ralph Steinman, whose discovery of dendritic cells earned the 2011 Nobel Prize in Physiology or Medicine. His work fundamentally changed the way modern medicine approaches immune regulation and anti-cancer defense.
In the context of gastric cancer, dendritic cell therapy is already in use in certified European clinics, showing:
- Strengthened tumor-specific immune responses
- Delayed recurrence after surgical and systemic treatment
- High tolerability, making it suitable even for weakened patients
This method is especially effective when integrated into a comprehensive treatment plan, as a maintenance or consolidation strategy to prevent disease progression.
TACE (Transarterial Chemoembolization): Localized Control for Liver Metastases and Innovative Neoadjuvant Therapy
Transarterial chemoembolization (TACE) is a minimally invasive, image-guided therapy designed to treat liver metastases by combining localized chemotherapy delivery with arterial embolization. The procedure involves selectively injecting chemotherapy agents into the hepatic artery branches that supply the tumor, followed by the administration of embolic material to block the blood flow. This dual mechanism ensures that the chemotherapeutic agents remain in contact with the tumor for an extended period while simultaneously depriving it of oxygen and nutrients.
TACE is particularly effective in gastric cancer with liver-dominant metastatic spread, where systemic therapy alone may be insufficient. Unlike systemic chemotherapy, TACE allows for high local drug concentrations with reduced systemic exposure, minimizing toxicity to healthy tissues and improving tolerability, even in patients with comorbidities or compromised performance status.
In clinical practice across European oncology centers, TACE has demonstrated:
- Local disease control in up to 70% of cases, often resulting in significant tumor shrinkage
- Normalization or reduction of elevated liver enzymes, indicating functional liver recovery
- Prolonged progression-free and overall survival, especially when integrated into multimodal treatment plans that may include systemic chemotherapy, immunotherapy, or ablation
Because of its favorable safety profile and measurable outcomes, TACE is now considered a standard therapeutic option for patients with unresectable liver metastases from gastric cancer. It is particularly valuable for patients who are ineligible for surgical resection or who require tumor burden reduction before systemic therapy.
A recent multicenter clinical study published in Journal of Clinical Oncology (2023) [5] confirms the effectiveness of TACE as a neoadjuvant therapy in gastric cancer. Among 43 patients, 42 (97.7%) underwent successful D2 resection following TACE. According to postoperative pathological analysis, tumor regression was observed in the majority of cases.
*Outcomes of transarterial chemoembolization in neoadjuvant therapy of patients with gastric cancer [5]
Given these outcomes, TACE is now increasingly recognized as a standard component in the multidisciplinary treatment of gastric cancer, particularly in patients with liver metastases or those who require tumor burden reduction prior to systemic therapy.
HIPEC (Hyperthermic Intraperitoneal Chemotherapy): Strength in Surgical Precision
HIPEC is a state-of-the-art intraoperative technique used to manage the peritoneal spread of gastric cancer. After removing visible tumor deposits through cytoreductive surgery, heated chemotherapy is circulated within the abdominal cavity to eliminate remaining microscopic disease.
Multiple European studies confirm:
- Median overall survival exceeding 20 months in carefully selected patients
- Reduced rates of peritoneal recurrence
- Favorable long-term outcomes when performed in experienced surgical centers
HIPEC has become a routinely available option in many European oncologic units and is included in several national treatment protocols for advanced gastric cancer with peritoneal involvement.
PIPAC (Pressurized Intraperitoneal Aerosol Chemotherapy): Minimally Invasive, Maximally Effective
PIPAC delivers chemotherapy as a pressurized aerosol directly into the peritoneal cavity via laparoscopy. This enhances tissue penetration and ensures uniform drug distribution while maintaining minimal systemic exposure.
It has shown:
- Objective tumor response rates in over 60% of patients with peritoneal metastases
- Median overall survival of 12-15 months, even in patients with advanced, treatment-resistant disease
- Excellent tolerability, allowing repeat treatments without hospitalization
PIPAC is now implemented in dozens of oncology centers across Europe and is seen as a reliable tool for disease control in peritoneal carcinomatosis, including gastric origin.
Stomach Cancer Treatment Abroad
For many patients diagnosed with stomach cancer, seeking cancer treatment abroad offers access to advanced therapies, multidisciplinary care, and specialized expertise that may not be available in their home countries. This decision is often motivated by a combination of medical needs, practical considerations, and the desire to pursue the most effective treatment options possible.
Patients choose international care to gain access to innovative therapies such as HIPEC, PIPAC, dendritic cell immunotherapy, TACE, and personalized chemotherapy – methods that are increasingly recognized in international oncology guidelines. Many leading clinics also participate in clinical trials and follow protocols aligned with the latest recommendations from ESMO and other global authorities.
International cancer centers are often high-volume institutions with teams dedicated specifically to treating gastric cancer. They typically offer shorter waiting times for diagnostic imaging, surgery, and novel therapies, and provide comprehensive logistical support, including translation services, coordinated care plans, and structured post-treatment follow-up.
Among the most sought-after destinations are Germany, South Korea, Japan, Israel, Turkey, Switzerland, and Austria – countries known for their advanced medical infrastructure, experience in managing complex cancer cases, and supportive environments for international patients.
Choosing to undergo cancer treatment abroad can offer broader therapeutic options, access to second opinions, and a chance to receive individualized care in world-class facilities. For many patients with advanced or treatment-resistant gastric cancer, it’s not just an alternative – it’s an opportunity to extend life and improve its quality.
| Characteristic | Standard Methods | Innovative Methods |
|---|---|---|
| 2-Year Survival Rate | ~30% for advanced-stage cases | ~55-65% in selected patients receiving multimodal therapies |
| Response Rate | Approx. 15% | 50-70% (depending on method and tumor profile) |
| Treatment Duration | 6-8 cycles over 4-6 months | Typically 3-5 sessions (e.g., PIPAC, TACE, dendritic immunotherapy) |
| Adverse Effects | High (nausea, immunosuppression, fatigue, hair loss) | Generally mild (localized pain, low systemic toxicity) |
Based on clinical data from Booking Health.
Medical Procedures Costs for Stomach Cancer
| Treatment Method | GERMANY* | Great Britain | USA |
|---|---|---|---|
| Standard Treatment | €80,000 - €150,000 full course | €90,000 - €165,000 full course | €100,000 - €180,000 full course |
| Innovative Methods | €25,000 - €60,000 full course | €70,000 - €120,000 full course | €100,000 - €150,000 full course |
Based on pricing insights from Booking Health. Final treatment costs may vary depending on individual clinical factors, length of hospital stay, required post-treatment supervision, and additional services such as diagnostics, travel assistance, and accommodation logistics.
From Uncertainty to Action: Majid Naji’s Path with Booking Health
When Majid Naji Al Obaidi began searching for stomach cancer treatment options abroad, he was faced with the complexity of organizing medical care in another country. His journey led him to the University Hospital Frankfurt am Main in Germany, with crucial support from Booking Health.
"Booking Health helped us to organize the treatment program at the University Hospital Frankfurt am Main, Germany," he shares. The process of arranging care overseas can often feel overwhelming, especially when it involves strict timelines, medical documentation, and international regulations. But with the right guidance, he was able to focus on what mattered most – getting the treatment he needed.
He credits the Booking Health team for their professionalism and responsiveness: "I thank all the company’s employees, especially Brother Muhammad and Sister Nour, for their professionalism and speed in responding and assisting in all visa procedures."
Majid Naji’s experience underscores the importance of having a reliable coordination partner when seeking medical care abroad. From handling critical visa arrangements to ensuring constant communication, Booking Health made the process smooth and manageable.
His words reflect not only gratitude but trust, a trust built on timely action, clear communication, and full organizational support at a time when clarity and peace of mind are absolutely essential.
A Medical Journey: Every Step of the Way With Booking Health
Finding the best treatment strategy for your clinical situation is a challenging task. Being already exhausted from multiple treatment sessions, having consulted numerous specialists, and having tried various therapeutic interventions, you may be lost in all the information given by the doctors. In such a situation, it is easy to choose a first-hand option or to follow standardized therapeutic protocols with a long list of adverse effects instead of selecting highly-specialized innovative treatment options.
To make an informed choice and get a personalized cancer management plan, which will be tailored to your specific clinical situation, consult medical experts at Booking Health. Being at the forefront of offering the latest medical innovations for already 12 years, Booking Health possesses solid expertise in creating complex cancer management programs in each individual case. As a reputable company, Booking Health offers personalized cancer treatment plans with direct clinic booking and full support at every stage, from organizational processes to assistance during treatment. We provide:
- Assessment and analysis of medical reports
- Development of the medical care program
- Selection of a suitable treatment location
- Preparation of medical documents and forwarding to a suitable clinic
- Preparatory consultations with clinicians for the development of medical care programs
- Expert advice during the hospital stay
- Follow-up care after the patient returns to their native country after completing the medical care program
- Taking care of formalities as part of the preparation for the medical care program
- Coordination and organization of the patient's stay in a foreign country
- Assistance with visas and tickets
- A personal coordinator and interpreter with 24/7 support
- Transparent budgeting with no hidden costs
Health is an invaluable aspect of our lives. Delegating management of something so fragile yet precious should be done only to experts with proven experience and a reputation. Booking Health is a trustworthy partner who assists you on the way of pursuing stronger health and a better quality of life. Contact our medical consultant to learn more about the possibilities of personalized treatment with innovative methods for gastric cancer with leading specialists in this field.
International Cancer Care: Patient Stories with Booking Health
Frequently asked Questions of Our Patients About Stomach Cancer Answered
Send request for treatmentThe best way to treat stomach cancer depends on its stage and the individual characteristics of the patient’s condition. Treatment options may involve surgery, chemotherapy, targeted therapy, or innovative methods such as HIPEC, PIPAC, or dendritic cell-based immunotherapy. Personalized care plans developed at leading oncology centers help treat stomach cancer more effectively and ensure the best possible outcomes.
Yes, stomach cancer can be curable, especially when diagnosed at an early stage. Curative treatment often involves surgical resection combined with chemotherapy or other modalities. Advanced cancer cases may benefit from advanced stomach cancer therapy methods like chemoembolization or immunotherapy using dendritic cells.
Common symptoms include abdominal pain, indigestion, weight loss, nausea, early satiety, and fatigue. If you experience persistent symptoms, early diagnosis is key to effective cancer treatment.
Yes, many patients choose treatment abroad to access advanced therapies not widely available in their home countries. Clinics in Germany offer advanced stomach cancer therapy options such as dendritic cell therapy, chemoembolization, and surgical oncology with full support for international patients.
Immunotherapy for gastric cancer, including dendritic cell-based treatment, is showing promising results in specific cases. It can be administered on its own or alongside other therapies. This personalized approach enhances the body’s immune response, helping it more effectively target and destroy cancer cells.
Leading hospitals in Europe specialize in stomach cancer surgery and comprehensive care. These centers often integrate innovative therapies like HIPEC or PIPAC during or after surgery, offering international patients access to world-class cancer treatment.
Survival rates vary depending on the stage at diagnosis and the treatment received. Early-stage stomach cancer has a significantly higher survival rate compared to advanced stages. Innovative methods such as chemoembolization, PIPAC, and dendritic cell therapy can improve outcomes even in metastatic cases.
Choose treatment abroad and you will for sure get the best results!
Authors:
This article was edited by medical experts, board-certified doctors Dr. Nadezhda Ivanisova, and Dr. Bohdan Mykhalniuk. For the treatment of the conditions referred to in the article, you must consult a doctor; the information in the article is not intended for self-medication!
Our editorial policy, which details our commitment to accuracy and transparency, is available here. Click this link to review our policies.
Sources:
[1] ECIS - European Cancer Information System. Stomach cancer burden in EU-27. https://ecis.jrc.ec.europa.eu/sites/default/files/2023-12/Stomach_cancer_2022_en.pdf
[2] National Comprehensive Cancer Network. NCCN Gastric cancer guidelines. https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1434
[3] Union for International Cancer Control (UICC). WCRF International releases a new report on stomach cancer. https://www.uicc.org/news/wcrf-international-releases-new-report-stomach-cancer
[4] European Society for Medical Oncology (ESMO). Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. https://www.esmo.org/guidelines/esmo-clinical-practice-guideline-gastric-cancer
[5] Journal of Clinical Oncology. Outcomes of transarterial chemoembolization in neoadjuvant therapy of patients with gastric cancer: A multicenter retrospective cohort study. https://ascopubs.org/doi/10.1200/JCO.2023.41.4_suppl.410
Read:
Stage 4 Stomach Cancer Treatment
Article menu:
- Understanding Stomach Cancer: Key Facts and Current Challenges
- Standard Treatment Options For Stomach Cancer
- Innovative Therapies for Gastric Cancer
- Stomach Cancer Treatment Abroad
- From Uncertainty to Action: Majid Naji’s Path with Booking Health
- A Medical Journey: Every Step of the Way With Booking Health
- Frequently asked Questions of Our Patients About Stomach Cancer Answered
Don't know where to start?
Contact Booking Health
